During the following 4 years, several other inhibitors of the PD-1 receptor or its ligands, PD-L1 and PD-L2, were approved, with pembrolizumab, atezolizumab, durvalumab, and avelumab showing significant enhancement in OS and Progression Free Survival (PFS) in several cancer types. The gene discussed is CD274; the disease is cancer.